{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:53:07Z","timestamp":1791067987288,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ek0109632"],"award-info":[{"award-number":["23ek0109632"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To conduct a nationwide questionnaire survey among patients with inherited retinal dystrophy (IRD) with the aim of investigating the percentage of patients requesting or not requesting genetic testing and clarifying the reasons underlying these preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>A questionnaire-based cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted a questionnaire survey targeting IRD patients aged 18 years or older. Participants were recruited from members of the Japanese Retinitis Pigmentosa Society, a patient advocacy organization for individuals with retinitis pigmentosa and other IRDs, and collaborating research institutions. The study announcement was also posted on the website of the Department of Ophthalmology, Faculty of Medicine, University of Miyazaki. Responses were collected in print, e-mail, and online formats between October 1, 2023 and March 31, 2025. The resulting data were statistically analyzed using simple tabulation and a logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 153 valid responses were obtained. The survey revealed that 86.3% of IRD patients requested genetic testing and the main reasons were personal motivation, such as: To identify the cause of the disease (84.8%), followed by: To obtain information for my future treatment, and :To obtain information regarding my future prognosis (both 81.8%). Conversely, the most common reason for not requesting the test was Genetic testing is pointless because there is no treatment (52.4%). Genetic testing was more likely to be requested by participants with greater knowledge of related terms. Among the 49 participants who had previously participated in gene analysis research, the explanation for the most frequent reason for satisfaction with the result was: The implications for children, grandchildren, and family members were clarified (73.7%), while the most frequent reason for dissatisfaction was: The diagnosis was not finalized (60.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present results indicate that the majority of patients possess a high level of interest and a positive attitude toward genetic testing. It is crucial to properly convey the significance of genetic testing and related information to patients, which will enable more patients to approach genetic testing positively and achieve a high level of satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01430-4","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:06:41Z","timestamp":1791007601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing awareness toward genetic testing among patients with inherited retinal dystrophy in Japan"],"prefix":"10.1007","author":[{"given":"Go","family":"Mawatari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji M.","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michikazu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"1430_CR1","first-page":"628","volume":"127","author":"Y Ikeda","year":"2023","unstructured":"Ikeda Y, Hotta Y, Kondo H, Nishiguchi K, Maeda A, Fujinami K, et al. Guidelines for genetic testing in inherited retinal dystrophy. Nippon Ganka Gakkai Zasshi. 2023;127:628\u201332 (in Japanese).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1430_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101244","volume":"100","author":"M Georgiou","year":"2024","unstructured":"Georgiou M, Robson AG, Fujinami K, de Guimar\u00e3es TAC, Fujinami-Yokokawa Y, Daich Varela M, et al. Phenotyping and genotyping inherited retinal diseases: molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retina Eye Res. 2024;100:101244.","journal-title":"Prog Retina Eye Res"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/gm155","volume":"2","author":"C Ayuso","year":"2010","unstructured":"Ayuso C, Millan JM. Retinitis pigmentosa and allied conditions today: a paradigm of translational research. Genome Med. 2010;2:34.","journal-title":"Genome Med"},{"key":"1430_CR4","doi-asserted-by":"crossref","unstructured":"Hanany M, Rivolta C, Sharon D. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proceedings of the National Academy of Sciences. 2020;117:2710\u20136","DOI":"10.1073\/pnas.1913179117"},{"key":"1430_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/343364a0","volume":"343","author":"T Dryja","year":"1990","unstructured":"Dryja T, McGee T, Reichel E, Hahn L, Cowley G, Yandell D, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990;343:364\u2013446.","journal-title":"Nature"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/347674a0","volume":"347","author":"F Cremers","year":"1990","unstructured":"Cremers F, van de Pol D, van Kerkhoff L, Wieringa B, Ropers H. Cloning of a gene that is rearranged in patients with choroideraemia. Nature. 1990;347:674\u20137.","journal-title":"Nature"},{"key":"1430_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"1430_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100876","volume":"5","author":"K Fujinami","year":"2025","unstructured":"Fujinami K, Akiyama K, Tsunoda K, Ito S, Seko N, Yamamoto S. Efficacy and safety of voretigene neparvovec in RPE65-retinopathy: results of a phase III trial in Japan. Ophthalmol Sci. 2025;5:100876.","journal-title":"Ophthalmol Sci"},{"key":"1430_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jgc4.1556","volume":"31","author":"A Inaba","year":"2022","unstructured":"Inaba A, Yoshida A, Maeda A, Kawai K, Kosugi S, Takahashi M. Perception of genetic testing among patients with inherited retinal disease: benefits and challenges in a Japanese population. J Genet Couns. 2022;31:860\u20137.","journal-title":"J Genet Couns"},{"key":"1430_CR10","first-page":"305","volume":"128","author":"A Maeda","year":"2024","unstructured":"Maeda A, Yokota S, Urakawa Y, Yoshida A, Inaba A, Kawai K, et al. Advanced medical care using gene panel testing: genetic testing for inherited retinal dystrophy. Nippon Ganka Gakkai Zasshi. 2024;128:305\u201310 (in Japanese).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1430_CR11","unstructured":"Nippon Research Center Ltd. Research on public awareness regarding genetic information in research and clinical practice. AMED commissioned survey report. Tokyo: Japan Agency for Medical Research and Development; 2018. https:\/\/mhlw-grants.niph.go.jp\/system\/files\/2016\/161031\/201605018A_upload\/201605018A0006.pdf. Accessed 16 Jan 2026. (in Japanese)"},{"key":"1430_CR12","unstructured":"Nippon Research Center Ltd. Public awareness survey on genetic information in research and medical care, 2017. Tokyo: Japan Agency for Medical Research and Development (AMED); 2018. https:\/\/www.amed.go.jp\/content\/000030390.pdf. Accessed 16 Jan 2026. (in Japanese)"},{"key":"1430_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1430_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12687-019-00415-w","volume":"10","author":"L Stafford","year":"2019","unstructured":"Stafford L, Flehr A, Judd F, Lindeman GJ, Gibson P, Komiti A, et al. Experiences and interpretations of BRCA1\/2 testing among women affected by breast or ovarian cancer who received a negative result. J Community Genet. 2019;10:501\u201314.","journal-title":"J Community Genet"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10897-007-9143-y","volume":"17","author":"KA Withrow","year":"2008","unstructured":"Withrow KA, Burton S, Arnos KS, Kalfoglou A, Pandya A. Consumer motivations for pursuing genetic testing and their preferences for the provision of genetic services for hearing loss. J Genet Couns. 2008;17:252\u201360.","journal-title":"J Genet Couns"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1265\/jjh.71.133","volume":"71","author":"C Nakashita","year":"2016","unstructured":"Nakashita C, Fujiwara Y, Lu X, Hisada A, Miyazaki W, Katoh T. Survey on the awareness of genetic testing in Japanese workers: the effect of participant characteristics on awareness. Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene). 2016;71:133\u20137 (in Japanese).","journal-title":"Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene)"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12687-024-00719-6","volume":"15","author":"M Uzair","year":"2024","unstructured":"Uzair M, Fatima R, Rafiq S, Jabeen M, Qaiser H, Arshad M, et al. Genetic testing perspectives in Pakistani population: a survey on knowledge, attitudes, awareness, and concerns. J Community Genet. 2024;15:631\u201340.","journal-title":"J Community Genet"},{"key":"1430_CR18","unstructured":"Seto Y, Oda K, Kage H, Ushiku A, Chan H, Akiyama N. Recommendations to promote cancer genomic medicine in Japan based on real-world surveys on comprehensive genomic profiling. Tokyo: Health and Labour Sciences Research Grant, Research on Promotion of Cancer Control Programs; 2023. https:\/\/www.genome-htu.jp\/wp\/wp-content\/uploads\/2023\/05\/recommendations_cancer_genomic_medicine_japan.pdf. Accessed 16 Jan 2026. (in Japanese)"},{"key":"1430_CR19","unstructured":"NTT DOCOMO Mobile Society Research Institute. Mobile Usage Trends 2024\u20132025: Mobile Society White Paper. Tokyo: NTT Publishing; 2024. https:\/\/www.moba-ken.jp\/whitepaper\/wp24\/pdf\/wp24_all.pdf. Accessed 16 Jan 2026. (in Japanese)"},{"key":"1430_CR20","first-page":"623","volume":"40","author":"T Miyake","year":"2023","unstructured":"Miyake T, Wada K. Low vision care with digital devices. J Eye. 2023;40:623\u20138 (in Japanese).","journal-title":"J Eye"},{"key":"1430_CR21","volume-title":"National health insurance medical free schedule: D006-30 hereditary retinal dystrophy genetic testing","author":"Ministry of Health, Labour and Welfare","year":"2024","unstructured":"Ministry of Health, Labour and Welfare. National health insurance medical free schedule: D006-30 hereditary retinal dystrophy genetic testing. Tokyo, Japan: Ministry of Health, Labour and Welfare; 2024."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01430-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:02:12Z","timestamp":1791064932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":21,"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01430-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G. Mawatari, None; T. Sakamoto, None; K. M. Nishiguchi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Sysmex); M. Akiyama, Grants or contracts (Alcon, Santen, MSD, Novartis), Consulting fees (Amgen), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Takeda, Senju, Chugai, Kowa, Bayer, Sysmex, Amgen), Support for attending meetings and\/or travel (Wakamoto), Endowed faculty member (Nidek); A. Oishi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis); K. Fujinami, None; A. Maeda, None; M. Nakai, None; Y. Ikeda, Grants or contracts (ID Pharma), Consulting fees (Novartis, Sysmex), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis).","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}